Dr. Stephanie Venn-Watson

Yeah, and that's where it gets to, conveniently, a longevity molecule must have number, what are we on, four, clinically relevant benefits within months. If a molecule says, hey, we target these mechanisms of longevity, but you're not really going to see anything, but you'll live longer. That doesn't, for Nick and I, that just is not what we were looking for.

Yeah, and that's where it gets to, conveniently, a longevity molecule must have number, what are we on, four, clinically relevant benefits within months. If a molecule says, hey, we target these mechanisms of longevity, but you're not really going to see anything, but you'll live longer. That doesn't, for Nick and I, that just is not what we were looking for.

We're looking for to say, can C15 actually have meaningful benefits, specifically with people with diseases? So again, caveating that as a supplement, supplement. Limits aren't intended to treat or prevent or to treat diseases.

We're looking for to say, can C15 actually have meaningful benefits, specifically with people with diseases? So again, caveating that as a supplement, supplement. Limits aren't intended to treat or prevent or to treat diseases.

We're looking for to say, can C15 actually have meaningful benefits, specifically with people with diseases? So again, caveating that as a supplement, supplement. Limits aren't intended to treat or prevent or to treat diseases.

But we're talking about the studies that have been done today and what we're seeing that, you know, we need C15 and putting C15 back into our system and optimizing those levels. We are seeing disease treating. And this is both in people. So let's take, for example, a clinical trial with Dr. Jeff Schwimmer, fatty liver disease, right? So that didn't exist.

But we're talking about the studies that have been done today and what we're seeing that, you know, we need C15 and putting C15 back into our system and optimizing those levels. We are seeing disease treating. And this is both in people. So let's take, for example, a clinical trial with Dr. Jeff Schwimmer, fatty liver disease, right? So that didn't exist.

But we're talking about the studies that have been done today and what we're seeing that, you know, we need C15 and putting C15 back into our system and optimizing those levels. We are seeing disease treating. And this is both in people. So let's take, for example, a clinical trial with Dr. Jeff Schwimmer, fatty liver disease, right? So that didn't exist.

Non-alcoholic fatty liver disease are now mazzled.

Non-alcoholic fatty liver disease are now mazzled.

Non-alcoholic fatty liver disease are now mazzled.

Maybe us docs inside should have been involved in branding a disease name.

Maybe us docs inside should have been involved in branding a disease name.

Maybe us docs inside should have been involved in branding a disease name.

So there you go. So I'll call it fatty liver disease, not associated with alcohol. So that wasn't known until Mayo Clinic published a paper in 1980 for the first 20 cases. And then, so since then, we move fast forward to today, the latest paper showed 38% of people globally have fatty liver disease.

So there you go. So I'll call it fatty liver disease, not associated with alcohol. So that wasn't known until Mayo Clinic published a paper in 1980 for the first 20 cases. And then, so since then, we move fast forward to today, the latest paper showed 38% of people globally have fatty liver disease.

So there you go. So I'll call it fatty liver disease, not associated with alcohol. So that wasn't known until Mayo Clinic published a paper in 1980 for the first 20 cases. And then, so since then, we move fast forward to today, the latest paper showed 38% of people globally have fatty liver disease.

So this has been a alarming rise in people with fatty liver disease, a percentage of which are progressed to steatohepatitis, inflammation, cirrhosis, becoming one of the leading causes of liver transplants and liver cancer.

So this has been a alarming rise in people with fatty liver disease, a percentage of which are progressed to steatohepatitis, inflammation, cirrhosis, becoming one of the leading causes of liver transplants and liver cancer.

So this has been a alarming rise in people with fatty liver disease, a percentage of which are progressed to steatohepatitis, inflammation, cirrhosis, becoming one of the leading causes of liver transplants and liver cancer.